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Pathogens are undeniably a critical environmental pressure influencing the evolution of humans and other animals;
the resulting genetic changes can significantly affect the outcome of an infection [1]. Fossil and genetic evidence sug-
gests that anatomically modern humans (Homo sapiens) arose in Africa approximately 200,000 years ago, following
approximately 6 million years of divergence from the shared great ape ancestors of Homo and chimpanzees (Pan
troglodytes) [2]. Unlike chimpanzees, who remained confined to their home continent, approximately 60,000 years
ago a single human populationmigrated out of Africa ultimately colonizing Eurasia, the Americas andOceania. The
long period since human–chimpanzee divergence combined with our subsequent worldwide spread has provided
ample opportunity for evolution to differentially adapt the two species to novel environments.
Hepatitis C virus (HCV), an enveloped positive-sense RNA virus in the family Flaviviridae (genus Hepacivirus),
is a blood-borne pathogen that is seemingly restricted to humans [3]. HCV currently infects an estimated 71 million
people worldwide (∼1% of the human population) resulting in 399,000 deaths annually due its efficient ability to
establish a chronic – typically life long – infection in the liver that can lead to fatal disease decades after primary
infection in the absence of treatment. HCV is highly diverse with at least eight distinct ‘genotypes’, which can be
over 30% different genetically from each other [4].
While HCV likely originated in the ‘Old World’ – with genotypes endemic only in sub-Saharan Africa and Asia
– a precise origin for the virus has not been identified [5]. Estimated timings for the expansion in HCV genomic
diversity suggest an origin between hundreds of thousands to thousands of years ago. Thus, current evidence fails to
distinguish between whether HCV has a ‘recent’ beginning in humans reflecting independent origins across Africa
and Asia or a single more ancient one, with HCV leaving Africa at the time of human migration. This pattern
of high genetic diversity in a single host species could be interpreted as evidence of either long-term coexistence
of HCV with humans, and/or relatively efficient spillover into humans from an as yet unknown animal reservoir
present in Africa and Asia; both scenarios indicate an intrinsic high level of HCV adaptation to humans. Of note,
hepaciviral sequences have been found across a very diverse selection of mammals [6] with the greatest diversity
found in bats and rodents, yet the closest relative to HCV is one found in horses and dogs but not primates.
To explore the virus’ host tropism, HCV has only been inoculated into species belonging to the Euarchontoglires
(rodents, rabbits, colugos, treeshrews and primates), for example: mice and woodchucks, treeshrews, and primates
(e.g., apes, Old and New World monkeys) [7–10]. Only chimpanzees and, to a much lesser degree, treeshrews are
permissive for HCV infection. Using in vivo and in vitro studies the lack of permissivity and susceptibility in lab
mice has been mapped to blocked viral entry and immune evasion [7]. Intriguingly, while permissive for chronic
HCV infection, rates of chronicity and associated disease differ in chimpanzees and treeshrews when compared
with humans. Most notably, HCV-infected chimpanzees have reduced rates of chronicity [11], disease [8], treatment
responses [12] and viral glycoprotein gene mutation rates indicative of enhanced immune pressure [13].
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By exploiting variation of HCV infection outcomes, combined with comparisons of whole genome sequences or
intraspecies genomic variation, research has started uncovering the specific host molecules that define species and
individual differences in HCV chronicity and pathogenesis [14]. Downstream experimental analysis can provide
additional functional evidence to support statistical associations. Initial studies demonstrated a significant role of
interindividual genetic differences in humans in the cellular immune response, including the T cell and natural
killer cell responses. More recently, genome-wide association studies in humans for HCV clearance revealed the
impact of innate immune signaling genes. This work identified a common loss-of-function frameshift variant in
the antiviral signaling protein gene IFNL4, associated with HCV clearance [15]. Somewhat counterintuitively for an
antiviral protein, production of IFNL4 is associated with reduced clearance of acute HCV infection and reduced
response to interferon alpha therapy, and has also been associated with reduced liver inflammation and disease [16].
A further common coding variant resulting from a substitution of proline at position 70 to serine (P70S) in IFNL4
was found to be associated with higher clearance rates than that of the ‘wild-type’ protein [17].
Sequencing of mammalian genomes and analysis of IFNL4 sequences showed that the gene has evolved under
purifying selection across a limited – but broad – selection of mammal species [18]. The IFNL4 loss-of-function
frameshift allele varies across human populations with its highest frequency in East Asia (>90%) and lowest in
sub-Saharan Africa (<40%). Loss of IFNL4 has evolved under positive selection in African and Asian populations
although the cause is unknown [18].
Intrigued by the role of IFNL4 variation in regulating HCV biology within humans and possibly between us
and other species, we have shown recently that human IFNL4 has evolved markedly reduced antiviral activity, in
comparison with IFNL4 from chimpanzees and to a lesser extent, from rhesus macaques [19]. This reduction in
activity resulted from a single amino acid change arising during human evolution (glutamic acid 154 to lysine;
E154K). E154 is almost 100% conserved in mammalian IFNL4 sequences, with humans being the exception.
Mechanistically, this negative-to-positive charge substitution impeded both protein secretion and potency likely
through disrupting key intramolecular bonds. Furthermore, our in vitro observations correlated with reduced
antiviral transcriptomic liver responses in humans compared with chimpanzees duringHCV infection. The reduced
activity is highly conserved in humans, with the E154 allele found in individuals with African descent, including
African–Americans and ‘pygmy’ hunter-gatherers from Central Africa (but not other African hunter-gatherers). We
also detected a very rare additional variant, L79F, in only one person from Sierra Leone inWest Africa. Additionally,
we were able to time the E154K event by identifying the variant in archaic human genomes (Neanderthal and
Denisovan) and the human frameshift TT allele, suggesting a date of occurrence at some point between 6 million
(post Homo-Pan divergence) and approximately 400,000 years ago (prior to human and Neanderthal/Denisovan
divergence). The E154K mutation seems to be the initial activity-attenuating event during human evolution. This
mutation likely occurred within Africa and was followed by rapid fixation in an early Homo ancestor before the
frameshift and P70S mutations. What drove this rapid evolution of an antiviral signaling molecule with less activity
is unknown.
Chimpanzees are considered a robust comparative model for HCV pathogenesis. Based on this, our work
suggests that although HCV is still able to establish a chronic infection in chimpanzees, their higher IFNL4 activity
compared with modern humans may favor the host and reduce the likelihood of chronicity and disease. Of note,
alongside enhanced antiviral gene expression in HCV-infected chimpanzee livers, we observed enhanced levels of
gene transcripts involved in T cell immune responses, which are critical for HCV clearance [19]. We thus propose
that humans evolved enhanced susceptibility to HCV relatively early during evolution. However, subsequent
evolution has led to both the seemingly maladaptive (E154K) and protective variants (IFNL4 loss-of-function,
P70S) coexisting in the same population resulting in a rich assemblage of variation in infection outcome. Therefore,
comparative genomics have revealed that human-specific genetic changes occurring following human–chimpanzee
divergence have both enhanced and reduced our immune defences to HCV.
Significant fundamental questions remain for even this most studied association: through what mechanism(s)
do IFNL4 and its variants affect HCV chronicity and pathogenesis? As chimpanzees are no longer subjected to
experimentation, and as the model would remain near impossible to genetically manipulate, this question and more
can only be addressed through the development of novel experimental approaches, which captures unique aspects of
HCV biology, such as chronicity and immunopathology. This could perhaps be achieved using other Hepacivirus–
host pairs, such as cows. Recently, it has been shown that IFNL4 drives HCV evolution within patients [20]. Thus,
a broader understanding of the complex relationship between both host and pathogen genetic and phenotypic
diversity should be pursued for HCV and other pathogens.
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Investigating the molecular determinants of host–pathogen interactions remains critical to understanding and
manipulating the outcomes of microbial infection and pathogenesis. Recent advances in comparative and functional
genomics from diverse host–pathogen pairs have begun to unravel the molecular mechanisms underlying outcome
of infection. Given the significant global health burden resulting from its capacity to establish a chronic infection,
studies on HCV are both needed and well-suited to continue providing critical insights into the workings of the
human immune system and our evolution.
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